Drug Information

Drug General Information
Drug ID
D01AIN
Former ID
DND000032
Drug Name
Fezakinumab
Synonyms
Fezakinumab (IV), fezakinumab (SC), ILV-094 (IV), ILV-094 (SC), PF-5212367 (IV) PF-5212367(SC)
Drug Type
Antibody
Indication Psoriasis [ICD9: 696; ICD10:L40] Phase 2 [524431]
Company
Wyeth; pfizer
Target and Pathway
Target(s) Interleukin-22 ligand Target Info [544277]
NetPath Pathway IL9 Signaling Pathway
References
Ref 524431ClinicalTrials.gov (NCT01941537) Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis. U.S. National Institutes of Health.
Ref 544277Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.